1
|
Rogers AD. The Impact of COVID-19 on Reconstructive Surgery for Burns and Complex Wounds. Plast Surg (Oakv) 2024; 32:163-165. [PMID: 38603175 PMCID: PMC9096170 DOI: 10.1177/22925503221094104] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Affiliation(s)
- Alan D. Rogers
- Ross Tilley Burn Centre, Sunnybrook Health Science Centre, Toronto, Ontario, Canada
- Division of Plastic and Reconstructive Surgery, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
2
|
Mantas A, Liu D, Otto CC, Heij LR, Heise D, Bruners P, Lang SA, Ulmer TF, Neumann UP, Bednarsch J. Time to surgery is not an oncological risk factor in patients with cholangiocarcinoma undergoing curative-intent liver surgery. Sci Rep 2024; 14:1644. [PMID: 38238432 PMCID: PMC10796920 DOI: 10.1038/s41598-023-50842-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Accepted: 12/27/2023] [Indexed: 01/22/2024] Open
Abstract
Surgical resection is the only option to achieve long-term survival in cholangiocellular carcinoma (CCA). Due to limitations of health care systems and unforeseeable events, e.g., the COVID pandemic, the time from diagnosis to surgery (time-to-surgery (TTS)) has gained great interest in malignancies. Thus, we investigated whether TTS is associated with the oncological outcome in patients who underwent surgery for CCA. A cohort of 276 patients undergoing curative-intent surgery for intrahepatic and perihilar CCA excluding individuals with neoadjuvant therapy and perioperative mortality between 2010 and 2021 were eligible for analysis. Patients were grouped according to TTS (≤ 30; 31-60; 61-90; > 90 days) and compared by Kruskal-Wallis-analysis. Survival was compared using Kaplan-Meier analysis and characteristics associated with cancer-specific survival (CSS), recurrence-free survival (RFS) and overall survival (OS) using Cox regressions. The median CSS was 39 months (3-year-CSS = 52%, 5-year-CSS = 42%) and the median RFS 20 months (3-year-CSS = 38%, 5-year-CSS = 33%). In univariable Cox regressions, TTS was not associated with CSS (p = 0.971) or RFS (p = 0.855), respectively. A grouped analysis with respect to TTS (≤ 30 days, n = 106; 31-60 days, n = 134; 61-90 days, n = 44; > 90 days, n = 29) displayed a median CSS of 38, 33, 51 and 41 months and median RFS of 17, 22, 28 and 20 months (p = 0.971 log rank; p = 0.520 log rank). No statistical difference regarding oncological risk factors were observed between the groups. This study is the first comprehensive analysis of TTS in CCA patients. Within a representative European cohort, TTS was not associated with earlier tumor recurrence or reduced CCS.
Collapse
Affiliation(s)
- Anna Mantas
- Department of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen, Germany
- Department of Surgery and Transplantation, University Hospital Essen, Essen, Germany
| | - Dong Liu
- Department of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen, Germany
| | - Carlos Constantin Otto
- Department of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen, Germany
- Department of Surgery and Transplantation, University Hospital Essen, Essen, Germany
| | - Lara Rosaline Heij
- Department of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen, Germany
- Department of Surgery and Transplantation, University Hospital Essen, Essen, Germany
- Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany
| | - Daniel Heise
- Department of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen, Germany
- Department of Surgery and Transplantation, University Hospital Essen, Essen, Germany
| | - Philipp Bruners
- Department of Diagnostic and Interventional Radiology, University Hospital RWTH Aachen, Aachen, Germany
| | - Sven Arke Lang
- Department of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen, Germany
- Department of Surgery and Transplantation, University Hospital Essen, Essen, Germany
| | - Tom Florian Ulmer
- Department of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen, Germany
- Department of Surgery and Transplantation, University Hospital Essen, Essen, Germany
| | - Ulf Peter Neumann
- Department of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen, Germany
- Department of Surgery and Transplantation, University Hospital Essen, Essen, Germany
- Department of Surgery, Maastricht University Medical Center (MUMC), Maastricht, The Netherlands
| | - Jan Bednarsch
- Department of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen, Germany.
- Department of Surgery and Transplantation, University Hospital Essen, Essen, Germany.
| |
Collapse
|
3
|
Badrudin D, Lesurtel M, Shrikhande S, Gallagher T, Heinrich S, Warner S, Chaudhari V, Koo D, Anantha S, Molina V, Calvo MP, Allard MA, Doussot A, Kourdouli A, Efanov M, Oddi R, Barros-Schelotto P, Erkan M, Lidsky M, Garcia F, Gelli M, Kaldarov A, Granero P, Meurisse N, Adam R. International Hepato-Pancreato-Billiary Association (IHPBA) registry study on COVID-19 infections in HPB surgery patients. HPB (Oxford) 2024; 26:102-108. [PMID: 38038484 DOI: 10.1016/j.hpb.2023.08.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/19/2022] [Revised: 06/11/2023] [Accepted: 08/10/2023] [Indexed: 12/02/2023]
Abstract
BACKGROUND In response to the pandemic, the International Hepato-Pancreato-Biliary Association (IHPBA) developed the IHPBA-COVID Registry to capture data on HPB surgery outcomes in COVID-positive patients prior to mass vaccination programs. The aim was to provide a tool to help members gain a better understanding of the impact of COVID-19 on patient outcomes following HPB surgery worldwide. METHODS An online registry updated in real time was disseminated to all IHPBA, E-AHPBA, A-HPBA and A-PHPBA members to assess the effects of the pandemic on the outcomes of HPB procedures, perioperative COVID-19 management and other aspects of surgical care. RESULTS One hundred twenty-five patients from 35 centres in 18 countries were included. Seventy-three (58%) patients were diagnosed with COVID-19 preoperatively. Operative mortality after pancreaticoduodenectomy and major hepatectomy was 28% and 15%, respectively, and 2.5% after cholecystectomy. Postoperative complication rates of pancreatic procedures, hepatic interventions and biliary interventions were respectively 80%, 50% and 37%. Respiratory complication rates were 37%, 31% and 10%, respectively. CONCLUSION This study reveals a high risk of mortality and complication after HPB surgeries in patient infected with COVID-19. The more extensive the procedure, the higher the risk. Nonetheless, an increased risk was observed across all types of interventions, suggesting that elective HPB surgery should be avoided in COVID positive patients, delaying it at distance from the viral infection.
Collapse
Affiliation(s)
- David Badrudin
- HPB & Transplant Surgery, Assistant Professor of Surgery, Department of Surgery, Université de Montréal, Montreal, Canada
| | - Mickaël Lesurtel
- Head of HPB Surgery & Liver Transplantation, Beaujon Hospital - University of Paris Cité, Paris, France
| | - Shailesh Shrikhande
- Deputy Director and Head of Cancer Surgery, Tata Memorial Hospital, Mumbai, India
| | | | | | | | - Vikram Chaudhari
- Gastrointestinal and HPB Surgical Oncology, Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India
| | - Donna Koo
- Northwell Health, Long Island Jewish Medical Center, New York, USA
| | - Sandeep Anantha
- Director of Surgical Oncology- LIJ Forest Hills Hospital, New York, USA
| | - Víctor Molina
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | | | - Marc-Antoine Allard
- Hôpital Paul Brousse, Centre Hépato-Biliaire, Université Paris-Saclay, AP-HP, Villejuif, France
| | | | | | | | - Ricardo Oddi
- Center for Clinical Medical Education and Research (CEMIC), Buenos Aires, Argentina
| | | | - Mert Erkan
- Koç University School of Medicine, Istanbul, Turkey
| | | | | | | | | | - Pablo Granero
- Central University Hospital of Asturias, Oviedo, Spain
| | | | - René Adam
- Hôpital Paul Brousse, Centre Hépato-Biliaire, Université Paris-Saclay, AP-HP, Villejuif, France.
| |
Collapse
|
4
|
Mika AP, Wollenman C, Steinle AM, Chanbour H, Vaughan W, Croft A, Lugo-Pico J, Zuckerman SL, Abtahi AM, Stephens BF. The Impact of the COVID-19 Pandemic on the Presentation of Patients With Spinal Metastases. Spine (Phila Pa 1976) 2023; 48:1599-1605. [PMID: 36255355 DOI: 10.1097/brs.0000000000004512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/12/2022] [Accepted: 09/08/2022] [Indexed: 02/01/2023]
Abstract
STUDY DESIGN Retrospective review. OBJECTIVE The aim was to determine if preoperative spinal instability neoplastic scores (SINSs) and Tokuhashi prognostication scores differed in patients receiving surgical care before and during the coronavirus disease-2019 (COVID-19) pandemic. SUMMARY OF BACKGROUND DATA The COVID-19 pandemic has caused delays in scheduling nonemergent surgeries. Delay in presentation and/or surgical treatment for oncology patients with metastatic spinal disease could result in progression of the disease, which can complicate surgical care and worsen patient outcomes. MATERIALS AND METHODS Retrospective review of electronic medical records between March 1, 2019 and March 1, 2021 at a tertiary medical center was performed to identify patients who underwent surgery for metastatic spine disease. Primary spinal tumors were excluded. Patients were separated into two groups base on their surgery date: before the COVID-19 pandemic (March 1, 2019-February 29, 2020) and during the COVID-19 pandemic (March 1, 2020-March 1, 2021). Primary outcomes included SINS and Tokuhashi scores. A variety of statistical tests were performed to compare the groups. RESULTS Fifty-two patients who underwent surgery before the COVID-19 pandemic were compared to 41 patients who underwent surgery during the COVID-19 pandemic. There was a significant difference between the before and during groups with respect to SINS (9.31±2.39 vs . 11.00±2.74, P =0.002) and Tokuhashi scores (9.27±2.35 vs . 7.88±2.85, P =0.012). Linear regression demonstrated time of surgery (before or during COVID-19 restrictions) was a significant predictor of SINS (β=1.55, 95% CI: 0.42-2.62, P =0.005) and Tokuhashi scores (β=-1.41, 95% CI: -2.49 to -0.34, P =0.010). CONCLUSIONS Patients with metastatic spinal disease who underwent surgery during the COVID-19 pandemic had higher SINS, lower Tokuhashi scores and similar Skeletal Oncology Research Group scores compared to patients who underwent surgery before the pandemic. This suggests the pandemic has impacted the instability of disease at presentation in patients with spinal metastases, but has not impacted surgical prognosis, as there were no differences in Skeletal Oncology Research Group scores and the difference in Tokuhashi scores is most likely not clinically significant.
Collapse
Affiliation(s)
- Aleksander P Mika
- Department of Orthopaedic Surgery, Vanderbilt University Medical Center, Nashville, TN
| | - Colby Wollenman
- Department of Orthopaedic Surgery, Vanderbilt University Medical Center, Nashville, TN
| | - Anthony M Steinle
- Department of Orthopaedic Surgery, Vanderbilt University Medical Center, Nashville, TN
| | - Hani Chanbour
- Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN
| | - Wilson Vaughan
- Department of Orthopaedic Surgery, Vanderbilt University Medical Center, Nashville, TN
| | - Andrew Croft
- Department of Orthopaedic Surgery, Vanderbilt University Medical Center, Nashville, TN
| | - Julian Lugo-Pico
- Department of Orthopaedic Surgery, Vanderbilt University Medical Center, Nashville, TN
| | - Scott L Zuckerman
- Department of Orthopaedic Surgery, Vanderbilt University Medical Center, Nashville, TN
- Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN
| | - Amir M Abtahi
- Department of Orthopaedic Surgery, Vanderbilt University Medical Center, Nashville, TN
- Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN
- Center for Musculoskeletal Research, Vanderbilt University Medical Center, Nashville, TN
| | - Byron F Stephens
- Department of Orthopaedic Surgery, Vanderbilt University Medical Center, Nashville, TN
- Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN
- Center for Musculoskeletal Research, Vanderbilt University Medical Center, Nashville, TN
| |
Collapse
|
5
|
Thomson WR, Puthucheary ZA, Wan YI. Critical care and pandemic preparedness and response. Br J Anaesth 2023; 131:847-860. [PMID: 37689541 PMCID: PMC10636520 DOI: 10.1016/j.bja.2023.07.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2023] [Revised: 06/21/2023] [Accepted: 07/23/2023] [Indexed: 09/11/2023] Open
Abstract
Critical care was established partially in response to a polio epidemic in the 1950s. In the intervening 70 yr, several epidemics and pandemics have placed critical care and allied services under extreme pressure. Pandemics cause wholesale changes to accepted standards of practice, require reallocation and retargeting of resources and goals of care. In addition to clinical acumen, mounting an effective critical care response to a pandemic requires local, national, and international coordination in a diverse array of fields from research collaboration and governance to organisation of critical care networks and applied biomedical ethics in the eventuality of triage situations. This review provides an introduction to an array of topics that pertain to different states of pandemic acuity: interpandemic preparedness, alert, surge activity, recovery and relapse through the literature and experience of recent pandemics including COVID-19, H1N1, Ebola, and SARS.
Collapse
Affiliation(s)
- William R Thomson
- Adult Critical Care Unit, Royal London Hospital, Whitechapel, London, UK; William Harvey Research Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.
| | - Zudin A Puthucheary
- Adult Critical Care Unit, Royal London Hospital, Whitechapel, London, UK; William Harvey Research Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK
| | - Yize I Wan
- Adult Critical Care Unit, Royal London Hospital, Whitechapel, London, UK; William Harvey Research Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK
| |
Collapse
|
6
|
Impact of the COVID-19 Pandemic on the Outcomes of Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: A Single Center Experience from a Developing Country. MEDICINA (KAUNAS, LITHUANIA) 2022; 58:medicina58121701. [PMID: 36556903 PMCID: PMC9786879 DOI: 10.3390/medicina58121701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/18/2022] [Revised: 11/05/2022] [Accepted: 11/15/2022] [Indexed: 11/24/2022]
Abstract
Background and Objectives: Treatment of cancer patients during the COVID-19 pandemic has been a challenge worldwide. In accordance with the current recommendations for hepatocellular carcinoma (HCC) management during the COVID-19 pandemic, loco-regional therapy such as transarterial chemoembolization (TACE) was proposed with the purpose of achieving local tumor control and improving overall survival. The aim of this prospective cohort study was to evaluate the outcomes of TACE treatment in patients with HCC during the COVID-19 pandemic in comparison with the outcomes of patients treated in the pre-pandemic period. Materials and Methods: Between September 2018 and December 2021, 154 patients were managed by serial TACE procedures for different liver tumors. Ninety-seven patients met the study criteria and were divided into two groups: the study group n = 49 (patients treated from May 2020 to December 2021); the control group n = 48 (patients treated from September 2018 to May 2020). Results: The mean waiting time for TACE was significantly longer in the study group compared to the control group (p < 0.001). No significant difference in survival between the groups is noted (log-rank test p = 0.823). In multivariate analysis, the MELD score (HR 1.329, 95% CI 1.140−1.548, p < 0.001) remained a significant predictor of mortality. Conclusions: COVID-19 pandemic did not affect the final outcome of TACE treatment.
Collapse
|
7
|
Li Z, Hu Y, Zeng M, Hu Q, Ye F, Liu R, Cai H, Li Q, Wang X. The role transition of radiotherapy for the treatment of liver cancer in the COVID-19 era. Front Oncol 2022; 12:976143. [PMID: 36185295 PMCID: PMC9516283 DOI: 10.3389/fonc.2022.976143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Accepted: 08/24/2022] [Indexed: 11/13/2022] Open
Abstract
The uncontrollable COVID-19 crises in the SARS-CoV-2 high-prevalence areas have greatly disrupted the routine treatment of liver cancer and triggered a role transformation of radiotherapy for liver cancer. The weight of radiotherapy in the treatment algorithm for liver cancer has been enlarged by the COVID-19 pandemic, which is helpful for the optimal risk-benefit profile.
Collapse
Affiliation(s)
- Zheng Li
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China
- Lanzhou Heavy Ion Hospital, Lanzhou, China
| | - Yue Hu
- Chengdu Women’s and Children’s Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - Ming Zeng
- Department of Radiation Oncology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, United States
| | - Qinyong Hu
- Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China
| | - Fei Ye
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China
| | - Ruifeng Liu
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China
- Lanzhou Heavy Ion Hospital, Lanzhou, China
| | - Hongyi Cai
- Department of Radiotherapy, Gansu Provincial Hospital, Lanzhou, China
| | - Qiang Li
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China
- Lanzhou Heavy Ion Hospital, Lanzhou, China
| | - Xiaohu Wang
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China
- Lanzhou Heavy Ion Hospital, Lanzhou, China
| |
Collapse
|
8
|
Karaca O, Rüggeberg JA, Bialas E, Schuster M. Critical Operations During the SARS-CoV-2 Pandemic. DEUTSCHES ARZTEBLATT INTERNATIONAL 2022; 119:558-559. [PMID: 36422869 PMCID: PMC9743215 DOI: 10.3238/arztebl.m2022.0225] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/07/2022] [Revised: 03/07/2022] [Accepted: 05/09/2022] [Indexed: 12/15/2022]
Affiliation(s)
| | | | | | - Martin Schuster
- Department of Anesthesiology, Intensive Care, Emergency Medicine and Pain Therapy, Kliniken Landkreis Karlsruhe, Furst-Stirum-Klinik Bruchsal and Rechbergklinik Bretten, Bruchsal, Germany
| |
Collapse
|
9
|
Yurttas C, Schleicher C, Fischer I, Meisner C, Nadalin S, Königsrainer A, Löffler MW, Quante M. Einfluss der Coronapandemie auf die Leberchirurgie und
Lebertransplantationen in Deutschland. Zentralbl Chir 2022; 147:354-360. [DOI: 10.1055/a-1845-1321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Zusammenfassung
Hintergrund Die Leberchirurgie ist durch ein hohes perioperatives Risiko
und einen großen Ressourcenaufwand geprägt, aber die Operationsindikation ist
oftmals alternativlos. Die SARS-CoV-2-Pandemie führte weltweit zu
Einschränkungen in der chirurgischen Patientenversorgung und stellte daher auch
die Leberchirurgie vor neue Herausforderungen. Welchen Einfluss die Pandemie
allerdings auf die Leberchirurgie in Deutschland insgesamt hatte, ist bislang
nur unzureichend bekannt.
Methoden Auf Basis der durch das Statistische Bundesamt (Destatis)
erfassten Daten zu Prozedurenschlüsseln (OPS-Codes) vollstationärer Patienten in
Deutschland aus den Jahren 2010–2020 sowie Daten zu Organtransplantationen der
Deutschen Stiftung Organtransplantation (DSO) wurde retrospektiv die Anzahl
leberchirurgischer Prozeduren in Deutschland zu Beginn der Pandemie mit den
Vorjahresdaten sowie mit Zahlen aus dem Eurotransplant-Raum verglichen.
Ergebnisse Entsprechend der durch das Statistische Bundesamt
dokumentierten Prozedurenschlüssel unterlagen Operationen an der Leber sowie
Lebertransplantationen in Deutschland in den Jahren 2010 bis 2020 einer
jährlichen Schwankung, die auch im Pandemiejahr 2020, im Gegensatz zu anderen
europäischen Ländern, unverändert geblieben ist. Die Entwicklung der
postmortalen Lebertransplantation sowie der Leberlebendspenden ist in
Deutschland, gemäß den Zahlen der DSO, auch im Jahr 2020 stabil geblieben.
Schlussfolgerungen Die Anzahl leberchirurgischer Eingriffe in Deutschland
unterlag bis 2020 einer dynamischen Entwicklung, die auch im 1. Pandemiejahr
2020 keine deutliche Veränderung gezeigt hat. Die häufigsten an der Leber
durchgeführten Operationen sowie die Lebertransplantation entwickelten sich auch
zu Beginn der Pandemie quantitativ weitgehend stabil. Die Veröffentlichung von
Daten zu den entsprechenden Prozedurenschlüsseln für das Jahr 2021 bleibt
abzuwarten, um die weitere Entwicklung der Leberchirurgie und -transplantation
in Deutschland während der SARS-CoV-2-Pandemie beurteilen zu können.
Collapse
Affiliation(s)
- Can Yurttas
- Klinik für Allgemeine, Viszeral- und
Transplantationschirurgie, Universitätsklinikum Tübingen, Tübingen,
Deutschland
| | - Christina Schleicher
- Deutsche Stiftung Organtransplantation - Region
Baden-Württemberg, Stuttgart, Deutschland
| | - Imma Fischer
- Institut für Klinische Epidemiologie und angewandte
Biometrie, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - Christoph Meisner
- Robert Bosch Gesellschaft für medizinische Forschung, Stuttgart,
Deutschland
| | - Silvio Nadalin
- Klinik für Allgemeine, Viszeral- und
Transplantationschirurgie, Universitätsklinikum Tübingen, Tübingen,
Deutschland
| | - Alfred Königsrainer
- Klinik für Allgemeine, Viszeral- und
Transplantationschirurgie, Universitätsklinikum Tübingen, Tübingen,
Deutschland
| | - Markus W. Löffler
- Abteilung für klinische Pharmakologie,
Universitätsklinikum Tübingen, Tübingen, Deutschland
- Exzellenzcluster iFIT (EXC2180) „Individualisierung von
Tumortherapien durch molekulare Bildgebung und funktionelle Identifizierung
therapeutischer Zielstrukturen (iFIT)", Eberhard-Karls-Universität Tübingen
Medizinische Fakultät, Tübingen, Germany
- Interfakultäres Institut für Zellbiologie, Abteilung
Immunologie, Eberhard Karls Universität Tübingen, Tübingen,
Deutschland
- Klinik für Allgemeine, Viszeral- und
Transplantationschirurgie, Universitätsklinikum Tübingen, Tübingen,
Deutschland
| | - Markus Quante
- Klinik für Allgemeine, Viszeral- und
Transplantationschirurgie, Universitätsklinikum Tübingen, Tübingen,
Deutschland
| |
Collapse
|
10
|
Chadha RM, Paulson MR, Avila FR, Torres-Guzman RA, Maita KC, Garcia JP, Forte AJ, Matcha GV, Pagan RJ, Maniaci MJ. A Virtual Hybrid Care Hotel Model Supports the Recovery of Post-procedural Patients with Mild to Severe Systemic Diseases. Am Surg 2022:31348221082271. [PMID: 35420494 DOI: 10.1177/00031348221082271] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Patients with mild to severe chronic systemic disease undergoing low-risk procedures are often hospitalized for observation. The Care Hotel is a novel virtual medicine hybrid model of care that offers patients a comfortable, out of hospital environment where they can receive both in-person and virtual care after a surgery or procedure. This study aimed to analyze if virtual hybrid post-procedure care in a hotel could be both conducted on and accepted by patients, even those with moderate to severe chronic diseases. METHODS This retrospective cohort study was conducted between July 23, 2020 and June 4, 2021 at Mayo Clinic in Florida, a 306-bed community academic hospital. We collected the sex, age, race, ethnicity, acceptance rate, ASA score, and primary procedure of patients using the Care Hotel. RESULTS Out of 392 patients, 272 (69.4%) opted for care in the program. Median patient age was 61.5 years, 59.56% were males, and 86.40% were white. We found that 50.37% had an ASA score of 2 and 43.4% had an ASA score of 3. Ten different surgical specialties were able to utilize the Care Hotel for care in 47 different procedure types. Urology had the most patients (n=70, 25.7%). Post-electrophysiologic procedures were the most common procedures (n=39, 14.3%). CONCLUSION Our virtual hybrid Care Hotel program was widely accepted by patients and could care for a multitude of post-operative procedures. Additionally, this novel program can care for patients with both mild and severe systemic diseases.
Collapse
Affiliation(s)
- Ryan M Chadha
- Department of Anesthesiology, 156400Mayo Clinic, Jacksonville, FL, USA
| | - Margaret R Paulson
- Division of Hospital Internal Medicine, 170021Mayo Clinic Health Systems, Eau Claire, WI, USA
| | - Francisco R Avila
- Division of Plastic Surgery, 156400Mayo Clinic, Jacksonville, FL, USA
| | | | - Karla C Maita
- Division of Plastic Surgery, 156400Mayo Clinic, Jacksonville, FL, USA
| | - John P Garcia
- Division of Plastic Surgery, 156400Mayo Clinic, Jacksonville, FL, USA
| | - Antonio J Forte
- Division of Plastic Surgery, 156400Mayo Clinic, Jacksonville, FL, USA.,Department of Neurological Surgery, 156400Mayo Clinic, Jacksonville, FL, USA
| | - Gautam V Matcha
- Division of Hospital Internal Medicine, 156400Mayo Clinic, Jacksonville, FL, USA
| | - Ricardo J Pagan
- Division of Hospital Internal Medicine, 156400Mayo Clinic, Jacksonville, FL, USA
| | - Michael J Maniaci
- Division of Hospital Internal Medicine, 156400Mayo Clinic, Jacksonville, FL, USA
| |
Collapse
|
11
|
Ashcraft K, Moretz C, Schenning C, Rojahn S, Vines Tanudtanud K, Magoncia GO, Reyes J, Marquez B, Guo Y, Erdemir ET, Hall TO. Unmanaged Pharmacogenomic and Drug Interaction Risk Associations with Hospital Length of Stay among Medicare Advantage Members with COVID-19: A Retrospective Cohort Study. J Pers Med 2021; 11:jpm11111192. [PMID: 34834543 PMCID: PMC8617857 DOI: 10.3390/jpm11111192] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2021] [Revised: 11/02/2021] [Accepted: 11/09/2021] [Indexed: 12/12/2022] Open
Abstract
Unmanaged pharmacogenomic and drug interaction risk can lengthen hospitalization and may have influenced the severe health outcomes seen in some COVID-19 patients. To determine if unmanaged pharmacogenomic and drug interaction risks were associated with longer lengths of stay (LOS) among patients hospitalized with COVID-19, we retrospectively reviewed medical and pharmacy claims from 6025 Medicare Advantage members hospitalized with COVID-19. Patients with a moderate or high pharmacogenetic interaction probability (PIP), which indicates the likelihood that testing would identify one or more clinically actionable gene–drug or gene–drug–drug interactions, were hospitalized for 9% (CI: 4–15%; p < 0.001) and 16% longer (CI: 8–24%; p < 0.001), respectively, compared to those with low PIP. Risk adjustment factor (RAF) score, a commonly used measure of disease burden, was not associated with LOS. High PIP was significantly associated with 12–22% longer LOS compared to low PIP in patients with hypertension, hyperlipidemia, diabetes, or chronic obstructive pulmonary disease (COPD). A greater drug–drug interaction risk was associated with 10% longer LOS among patients with two or three chronic conditions. Thus, unmanaged pharmacogenomic risk was associated with longer LOS in these patients and managing this risk has the potential to reduce LOS in severely ill patients, especially those with chronic conditions.
Collapse
Affiliation(s)
- Kristine Ashcraft
- Invitae Corporation, San Francisco, CA 94103, USA; (C.M.); (C.S.); (S.R.)
- Correspondence: ; Tel.: +1-415-374-7782
| | - Chad Moretz
- Invitae Corporation, San Francisco, CA 94103, USA; (C.M.); (C.S.); (S.R.)
| | | | - Susan Rojahn
- Invitae Corporation, San Francisco, CA 94103, USA; (C.M.); (C.S.); (S.R.)
| | - Kae Vines Tanudtanud
- OptumLabs at UnitedHealth Group, Minnetonka, MN 55343, USA; (K.V.T.); (G.O.M.); (J.R.); (B.M.); (Y.G.); (E.T.E.); (T.O.H.)
| | - Gwyn Omar Magoncia
- OptumLabs at UnitedHealth Group, Minnetonka, MN 55343, USA; (K.V.T.); (G.O.M.); (J.R.); (B.M.); (Y.G.); (E.T.E.); (T.O.H.)
| | - Justine Reyes
- OptumLabs at UnitedHealth Group, Minnetonka, MN 55343, USA; (K.V.T.); (G.O.M.); (J.R.); (B.M.); (Y.G.); (E.T.E.); (T.O.H.)
| | - Bernardo Marquez
- OptumLabs at UnitedHealth Group, Minnetonka, MN 55343, USA; (K.V.T.); (G.O.M.); (J.R.); (B.M.); (Y.G.); (E.T.E.); (T.O.H.)
| | - Yinglong Guo
- OptumLabs at UnitedHealth Group, Minnetonka, MN 55343, USA; (K.V.T.); (G.O.M.); (J.R.); (B.M.); (Y.G.); (E.T.E.); (T.O.H.)
| | - Elif Tokar Erdemir
- OptumLabs at UnitedHealth Group, Minnetonka, MN 55343, USA; (K.V.T.); (G.O.M.); (J.R.); (B.M.); (Y.G.); (E.T.E.); (T.O.H.)
| | - Taryn O. Hall
- OptumLabs at UnitedHealth Group, Minnetonka, MN 55343, USA; (K.V.T.); (G.O.M.); (J.R.); (B.M.); (Y.G.); (E.T.E.); (T.O.H.)
| |
Collapse
|
12
|
van der Hage J, Sandrucci S, Audisio R, Wyld L, Søreide K, Amaral T, Audisio R, Bahadoer V, Beets G, Benstead K, Berge Nilsen E, Bol K, Brandl A, Braun J, Cufer T, Dopazo C, Edhemovic I, Eriksen JG, Fiore M, van Ginhoven T, Gonzalez-Moreno S, van der Hage J, Hutteman M, Masannat Y, Onesti EC, Rau B, De Reijke T, Rubio I, Ruurda J, Sandrucci S, Soreide K, Stattner S, Trapani D, D'Ugo D, Vriens M, Wyld L, Zahl Eriksson AG. The ESSO core curriculum committee update on surgical oncology. Eur J Surg Oncol 2021; 47:e1-e30. [PMID: 34657781 DOI: 10.1016/j.ejso.2021.10.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2021] [Revised: 09/29/2021] [Accepted: 10/05/2021] [Indexed: 11/30/2022] Open
Abstract
INTRODUCTION Surgical oncology is a defined specialty within the European Board of Surgery within the European Union of Medical Specialists (UEMS). Variation in training and specialization still occurs across Europe. There is a need to align the core knowledge needed to fulfil the criteria across subspecialities in surgical oncology. MATERIAL AND METHODS The core curriculum, established in 2013, was developed with contributions from expert advisors from within the European Society of Surgical Oncology (ESSO), European Society for Radiotherapy and Oncology (ESTRO) and European Society of Medical Oncology (ESMO) and related subspeciality experts. RESULTS The current version reiterates and updates the core curriculum structure needed for current and future candidates who plans to train for and eventually sit the European fellowship exam for the European Board of Surgery in Surgical Oncology. The content included is not intended to be exhaustive but, rather to give the candidate an idea of expectations and areas for in depth study, in addition to the practical requirements. The five elements included are: Basic principles of oncology; Disease site specific oncology; Generic clinical skills; Training recommendations, and, lastly; Eligibility for the EBSQ exam in Surgical Oncology. CONCLUSIONS As evidence-based care for cancer patients evolves through research into basic science, translational research and clinical trials, the core curriculum will evolve, mature and adapt to deliver continual improvements in cancer outcomes for patients.
Collapse
Affiliation(s)
- Jos van der Hage
- Department of Surgery, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands.
| | - Sergio Sandrucci
- Surgical Oncology Unit, City of Health and Science, University of Turin, Turin, Italy
| | - Riccardo Audisio
- Department of Surgery, Sahlgrenska University Hospital, University of Gothenburg, Sweden
| | - Lynda Wyld
- Department of Oncology and Metabolism, Sheffield University, Sheffield, United Kingdom
| | - Kjetil Søreide
- Department of Gastrointestinal Surgery, HPB unit, Stavanger University Hospital, Stavanger, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway.
| | | | - Teresa Amaral
- Dermatology, Eberhard Karls Universitat Tubingen, Tubingen, Germany
| | | | - Viren Bahadoer
- Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands
| | - Geerard Beets
- Department of Surgery, Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - Kim Benstead
- Gloucestershire Oncology Centre, Cheltenham General Hospital, United Kingdom
| | - Elisabeth Berge Nilsen
- Department of Obstetrics and Gynecology, Stavanger University Hospital, Stavanger, Norway
| | - Kalijn Bol
- Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Andreas Brandl
- Department of Surgery, Campus Virchow-Klinikum and Charité Campus Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany; Digestive Unit, Champalimaud Foundation, Lisbon, Portugal
| | - Jerry Braun
- Department of Thoracic Surgery, Leiden University Medical Center, Leiden, the Netherlands
| | - Tanja Cufer
- University Clinic Golnik, University of Ljubljana, 4204 Ljubljana, Slovenia
| | - Cristina Dopazo
- Department of Hepato-Pancreato-Biliary and Transplant Surgery, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - Ibrahim Edhemovic
- Department of Surgery, Institute of Oncology Ljubljana, Ljubljana, Slovenia
| | - Jesper Grau Eriksen
- Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark
| | - Marco Fiore
- Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Tessa van Ginhoven
- Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
| | | | - Jos van der Hage
- Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands
| | - Merlijn Hutteman
- Department of Thoracic Surgery, Leiden University Medical Center, Leiden, the Netherlands
| | - Yazan Masannat
- University of Aberdeen, School of Medicine, Medical Science and Nutrition, Aberdeen, UK
| | - Elisa Concetta Onesti
- Department of Clinical and Molecular Medicine, "Sapienza" University of Rome, Rome, Italy
| | - Beate Rau
- Department of General Surgery, Charité University of Berlin, Berlin, Germany
| | - Theo De Reijke
- Department of Urology, Amsterdam UMC, Amsterdam, the Netherlands
| | - Isabel Rubio
- Breast Surgical Oncology, Clínica Universidad de Navarra, Madrid, Universidad de Navarra, Spain
| | - Jelle Ruurda
- Visceral Sarcoma Surgery Unit, Città della Salute e della Scienza, Turin, Italy
| | - Sergio Sandrucci
- Department of Gastrointestinal Surgery, Stavanger University Hospital, Stavanger, Norway
| | - Kjetil Soreide
- Department of Surgery, Salzkammergutklinikum, Standort Vöcklabruck, Oberösterreich, Austria
| | - Stefan Stattner
- Department of Surgery, Paracelsus Medical University Salzburg, Salzburg, Austria; New drugs development for innovative therapies, European Institute of Oncology, IRCCS, Milano, Italy
| | - Dario Trapani
- General Surgery Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University, 00168 Rome, Italy
| | - Domenico D'Ugo
- Department of Surgery, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands
| | - Menno Vriens
- Department of Surgery, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands
| | - Lynda Wyld
- Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
| | | |
Collapse
|
13
|
Hillebrandt K, Nevermann N, Globke B, Moosburner S, Schmelzle M, Pratschke J. [Impact of the COVID-19 pandemic on hepato-pancreato-biliary surgery and organ transplantation]. Chirurg 2021; 92:918-923. [PMID: 34297148 PMCID: PMC8299733 DOI: 10.1007/s00104-021-01463-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/22/2021] [Indexed: 12/12/2022]
Abstract
Hintergrund und Ziel der Arbeit Im Rahmen der COVID-19(„coronavirus disease 2019“)-Pandemie wurden weitreichende Ressourceneinschränkungen und -umverteilungen innerhalb des Gesundheitssystems notwendig. Diese Übersichtsarbeit beleuchtet die direkten und indirekten Folgen der COVID-19-Pandemie auf die Bereiche der hepatopankreatobiliären (HPB)-Chirurgie und Organtransplantation unter Berücksichtigung aktueller Literatur und veröffentlichter Expertenmeinungen nationaler und internationaler Fachgesellschaften. Entwicklungen der Operationszahlen wurden über die Eurotransplant Statistics Report Library und eine zentrumsinterne Auswertung HPB-chirurgischer Eingriffe analysiert. Ergebnisse In den Bereichen der HPB-Chirurgie und Organtransplantation zeigte sich vor allem in der ersten Pandemiewelle an vielen Zentren ein deutlicher Einbruch der Eingriffszahlen. Interessanterweise konnte meist kein kompensatorischer Zuwachs der Operationen in den Folgemonaten verzeichnet werden. Im Jahrestrend zeigen sich somit leicht rückläufige Zahlen. Ob dieser Trend auf eine erhöhte Sterblichkeit durch verschobene Operationen und geänderte Therapieregimes zurückzuführen ist, lässt sich derzeit zumindest nicht ausschließen. Eine SARS-CoV-2(„severe acute respiratory syndrome coronavirus 2“)-Infektion ist auf jeden Fall mit einem komplikativen Verlauf assoziiert, insbesondere im perioperativen Verlauf und nach Transplantation. Diskussion Aufgrund des erhöhten Risikoprofils der genannten Patientengruppen besteht ein erhöhtes Risiko für einen schweren COVID-19-Verlauf. Dies muss bei der Abwägung von Therapiealternativen, der Schutzempfehlungen und der Priorisierung bei Impfungen in Betracht gezogen werden.
Collapse
Affiliation(s)
- K Hillebrandt
- Chirurgische Klinik, Campus Charité Mitte
- Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Deutschland
| | - N Nevermann
- Chirurgische Klinik, Campus Charité Mitte
- Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Deutschland
| | - B Globke
- Chirurgische Klinik, Campus Charité Mitte
- Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Deutschland
| | - S Moosburner
- Chirurgische Klinik, Campus Charité Mitte
- Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Deutschland
| | - M Schmelzle
- Chirurgische Klinik, Campus Charité Mitte
- Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Deutschland
| | - Johann Pratschke
- Chirurgische Klinik, Campus Charité Mitte
- Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Deutschland.
| |
Collapse
|
14
|
Akova B, Kıvanç SA. Ophthalmic Emergencies and Effects of Different Quarantine Models During the COVID-19 Pandemic. Med Sci Monit 2021; 27:e931967. [PMID: 33980807 PMCID: PMC8130502 DOI: 10.12659/msm.931967] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Background The aim of this study was to evaluate the epidemiological features of the patients admitted to our emergency department (ED) during the COVID-19 pandemic in March, April, and May 2020, compare them with the patients in March, April, and May 2019, and to investigate the effect of various quarantine models. Material/Methods The records of 1206 eligible patients were reviewed. Age groups were divided according to their quarantine status. We recorded the reasons for patient presentation to the ED, the average number of patients in age groups according to quarantine days, and the problems reported by patients who presented to the ED according to quarantine days. Results We enrolled 3016 of 3123 patients. The mean age was 36.4±17.3 years in 2019 and 37.8±16.4 years during the pandemic period (P=0.031). While 73.1% of the ED presentations were due to ocular trauma in 2019, it decreased to 70.7% in 2020. The proportion of those who presented to the ED during the weekend was 30.6% in 2019, but decreased to 23.9% in 2020 (<0.001). While 84.8% of trauma patients were ages 19–64 years in 2019, this rate increased to 88.9% during the pandemic (P=0.067). Non-trauma emergencies were more common than trauma emergencies in both periods in those over the age of 65 years. During the pandemic period, admissions to the ED were decreased in the quarantined age groups (P=0.001). Conclusions The changes in the number and characteristic of admissions for ophthalmic emergencies during the pandemic period may help planning allocation of healthcare personnel and resources in outpatient and emergency clinics.
Collapse
Affiliation(s)
- Berna Akova
- Department of Ophthalmology, Bursa Uludağ University, School of Medicine, Bursa, Turkey
| | - Sertaç Argun Kıvanç
- Department of Ophthalmology, Bursa Uludağ University, School of Medicine, Bursa, Turkey
| |
Collapse
|
15
|
Malik A, Thanekar U, Amarachintha S, Mourya R, Nalluri S, Bondoc A, Shivakumar P. "Complimenting the Complement": Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma. Front Oncol 2021; 10:627701. [PMID: 33718121 PMCID: PMC7943925 DOI: 10.3389/fonc.2020.627701] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Accepted: 12/22/2020] [Indexed: 12/15/2022] Open
Abstract
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and a leading cause of death in the US and worldwide. HCC remains a global health problem and is highly aggressive with unfavorable prognosis. Even with surgical interventions and newer medical treatment regimens, patients with HCC have poor survival rates. These limited therapeutic strategies and mechanistic understandings of HCC immunopathogenesis urgently warrant non-palliative treatment measures. Irrespective of the multitude etiologies, the liver microenvironment in HCC is intricately associated with chronic necroinflammation, progressive fibrosis, and cirrhosis as precedent events along with dysregulated innate and adaptive immune responses. Central to these immunological networks is the complement cascade (CC), a fundamental defense system inherent to the liver which tightly regulates humoral and cellular responses to noxious stimuli. Importantly, the liver is the primary source for biosynthesis of >80% of complement components and expresses a variety of complement receptors. Recent studies implicate the complement system in liver inflammation, abnormal regenerative responses, fibrosis, carcinogenesis, and development of HCC. Although complement activation differentially promotes immunosuppressive, stimulant, and angiogenic microenvironments conducive to HCC development, it remains under-investigated. Here, we review derangement of specific complement proteins in HCC in the context of altered complement regulatory factors, immune-activating components, and their implications in disease pathogenesis. We also summarize how complement molecules regulate cancer stem cells (CSCs), interact with complement-coagulation cascades, and provide therapeutic opportunities for targeted intervention in HCC.
Collapse
Affiliation(s)
- Astha Malik
- Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States
| | - Unmesha Thanekar
- Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States
| | - Surya Amarachintha
- Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States
| | - Reena Mourya
- Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States
| | - Shreya Nalluri
- Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States
| | - Alexander Bondoc
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States
- Division of Pediatric General and Thoracic Surgery, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States
| | - Pranavkumar Shivakumar
- Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States
| |
Collapse
|